Neos Therapeutics (NEOS) Announces Earnings Results, Misses Expectations By $0.03 EPS
Neos Therapeutics (NASDAQ:NEOS) released its earnings results on Friday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03), MarketWatch Earnings reports. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $14.80 million. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%.
NEOS traded up $0.01 during trading on Friday, reaching $2.59. 651,079 shares of the company’s stock were exchanged, compared to its average volume of 621,268. Neos Therapeutics has a 1 year low of $2.27 and a 1 year high of $11.69. The firm has a market capitalization of $83.38 million, a PE ratio of -0.97 and a beta of 0.44.
A number of research firms recently commented on NEOS. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of Neos Therapeutics in a research note on Friday. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. Zacks Investment Research raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Finally, Wells Fargo & Co reduced their price target on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.50.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.